Why Baxter’s GMP False Claims Settlement Was Smaller Than Those Of GSK, Ranbaxy
Executive Summary
Baxter resolves US plant’s GMP whistleblower allegations for just $18m, a bargain compared to the $750m GlaxoSmithKline paid in 2010 and the $500m Ranbaxy paid in 2013. One reason: it was more narrowly focused.
You may also be interested in...
Ranbaxy’s $500 Million Settlement Includes Criminal Penalties
The generic drug maker’s Ranbaxy USA Inc. subsidiary pleads guilty to seven felony counts brought in connection with a longstanding government investigation into data integrity issues and manufacturing violations at two Indian sites, but while the settlement eliminates some worries for the firm, operations still face the weight of a FDA consent decree.
U.S. FDA Issues Life Ban For 27 Ranbaxy Products, Company Says Move To Have “Negligible Commercial Impact”
A consent decree signed in January specified Ranbaxy must never submit another application for the withdrawn products.